Shannon Parisotto, an executive at Charles River Laboratories International, Inc., has reported recent stock transactions in an SEC filing. This activity is significant as it underscores the ongoing trading and ownership changes within the life sciences industry.
Background
Charles River Laboratories International, Inc. is a key player in the life sciences sector, specifically categorized under services for commercial physical and biological research. The company is known for its comprehensive laboratory services, supporting pharmaceutical and biotechnology companies in their research and development efforts. The recent filing is part of a series of disclosures made by Parisotto, reflecting the company's commitment to transparency.
What the Filing Says
The filing, dated October 23, 2026, reveals that Parisotto engaged in both the acquisition and disposal of common stock on October 21, 2026. Specifically, Parisotto acquired 2,156 shares at a price of $244.41 each and disposed of the same number of shares at a price of $344.41 each. Following these transactions, Parisotto now holds a total of 6,963 shares directly. The filing notes, "This exercise and sale occurred pursuant to a Rule 10b5-1 Trading Plan that was initially adopted on March 4, 2026." This plan allows for pre-scheduled trading, which can help avoid allegations of insider trading.
Impact
These transactions may affect investor confidence and perceptions of the company, as insider trading activity can signal management's confidence in the company's future. The life sciences sector, where Charles River operates, is highly competitive, and such disclosures are essential for maintaining investor trust.
What's Next
The filing does not specify what happens next regarding further transactions or any upcoming announcements from Charles River Laboratories.